Molecular pathology and epidemiology of nephrogenic rests and Wilms tumors

Journal of Pediatric Hematology/Oncology

Volumn 29, Issue 9, 2007, Pages 589-594

  Fukuzawa, Ryuji ^a   Reeve, Anthony E ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Beckwith Wiedemann syndrome; H19; IGF2; Imprinting; WT1

Indexed keywords

SOMATOMEDIN B;

ASIAN; EPIGENETICS; ETHNIC OR RACIAL ASPECTS; GENE FREQUENCY; GENETIC DIFFERENCE; HISTOPATHOLOGY; HUMAN; INCIDENCE; INTRALOBAR NEPHROGENIC REST; LEARNING; MOLECULAR GENETICS; NEPHROBLASTOMA; NEPHROGENIC REST; PERILOBAR NEPHROGENIC REST; PRIORITY JOURNAL; REVIEW;

ASIAN CONTINENTAL ANCESTRY GROUP; CHILD; GENOMIC IMPRINTING; HUMANS; KIDNEY NEOPLASMS; MALE; NEPHRONS; PRECANCEROUS CONDITIONS; PROTEINS; WILMS TUMOR;

EID: 34548458923     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/01.mph.0000212981.67114.ec     Document Type: Review

References (51)

1. Beckwith JB, Kiviat NB, Bonadio JF. Nephrogenic rests, nephroblastomatosis, and the pathogenesis of Wilms' tumor. Pediatr Pathol. 1990;10:1-36.
2. Breslow N, Olshan A, Beckwith JB, et al. Epidemiology of Wilms tumor. Med Pediatr Oncol. 1993;21:172-181.
3. Beckwith JB. Nephrogenic rests and the pathogenesis of Wilms tumor: developmental and clinical considerations. Am J Med Genet. 1998;79:268-273.
4. Fukuzawa R, Breslow NE, Morison IM, et al. Epigenetic differences between Wilms' tumours in white and east-Asian children. Lancet. 2004;363:446-451.
5. Weksberg R, Nishikawa J, Caluseriu O, et al. Tumor development in the Beckwith-Wiedemann syndrome is associated with a variety of constitutional molecular 11p15 alterations including imprinting defects of KCNQ1OT1. Hum Mol Genet. 2001;10:2989-3000.
6. Kalapurakal JA, Dome JS, Perlman EJ, et al. Management of Wilms' tumour: current practice and future goals. Lancet Oncol. 2004;5:37-46.
7. Knudson AG Jr, Strong LC. Mutation and cancer: a model for Wilms' tumor of the kidney. J Natl Cancer Inst. 1972;48:313-324.
8. Grundy P, Wilson B, Telzerow P, et al. Uniparental disomy occurs infrequently in Wilms tumor patients. Am J Hum Genet. 1994;54:282-289.
9. Dao D, Walsh CP, Yuan L, et al. Multipoint analysis of human chromosome 11p15/mouse distal chromosome 7: inclusion of H19/IGF2 in the minimal WT2 region, gene specificity of H19 silencing in Wilms' tumorigenesis and methylation hyper-dependence of H19 imprinting. Hum Mol Genet. 1999;8:1337-1352.
10. Grundy P, Telzerow P, Moksness J, et al. Clinicopathologic correlates of loss of heterozygosity in Wilm's tumor: a preliminary analysis. Med Pediatr Oncol. 1996;27:429-433.
11. Schroeder WT, Chao LY, Dao DD, et al. Nonrandom loss of maternal chromosome 11 alleles in Wilms tumors. Am J Hum Genet. 1987;40:413-420.
12. Wilkins RJ. Genomic imprinting and carcinogenesis. Lancet. 1988;1:329-331.
13. Little M, van Heyningen V, Hastie N. Dads and disomy and disease. Nature. 1991;351:609-610.
14. Henry I, Bonaiti-Pellie C, Chehensse V, et al. Uniparental paternal disomy in a genetic cancer-predisposing syndrome. Nature. 1991;351:665-667.
15. Henry I, Puech A, Riesewijk A, et al. Somatic mosaicism for partial paternal isodisomy in Wiedemann-Beckwith syndrome: a postfertilization event. Eur J Hum Genet. 1993;1:19-29.
16. Pelletier J, Bruening W, Li FP, et al. WT1 mutations contribute to abnormal genital system development and hereditary Wilms' tumour. Nature. 1991;353:431-434.
17. Schumacher V, Schneider S, Figge A, et al. Correlation of germ-line mutations and two-hit inactivation of the WT1 gene with Wilms tumors of stromal-predominant histology. Proc Natl Acad Sci U S A. 1997;94:3972-3977.
18. Charles AK, Brown KW, Berry PJ. Microdissecting the genetic events in nephrogenic rests and Wilms' tumor development. Am J Pathol. 1998;153:991-1000.
19. Koesters R, Ridder R, Kopp-Schneider A, et al. Mutational activation of the beta-catenin proto-oncogene is a common event in the development of Wilms' tumors. Cancer Res. 1999;59:3880-3882.
20. Maiti S, Alam R, Amos CI, et al. Frequent association of beta-catenin and WT1 mutations in Wilms tumors. Cancer Res. 2000;60:6288-6292.
21. Fukuzawa R, Heathcott RW, Sano M, et al. Myogenesis in Wilms' tumors is associated with mutations of the WT1 gene and activation of Bcl-2 and the Wnt signaling pathway. Pediatr Dev Pathol. 2004;7:125-137.
22. Li CM, Kim CE, Margolin AA, et al. CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms' tumors. Am J Pathol. 2004;165:1943-1953.
23. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature. 2005;434:843-850.
24. Scelfo RA, Schwienbacher C, Veronese A, et al. Loss of methylation at chromosome 11p15.5 is common in human adult tumors. Oncogene. 2002;21:2564-2572.
25. Zemel S, Bartolomei MS, Tilghman SM. Physical linkage of two mammalian imprinted genes, H19 and insulin-like growth factor 2. Nat Genet. 1992;2:61-65.
26. Frevel MA, Sowerby SJ, Petersen GB, et al. Methylation sequencing analysis refines the region of H19 epimutation in Wilms tumor. J Biol Chem. 1999;274:29331-29340.
27. Hark AT, Schoenherr CJ, Katz DJ, et al. CTCF mediates methylation-sensitive enhancer-blocking activity at the H19/Igf2 locus. Nature. 2000;405:486-489.
28. Bell AC, Felsenfeld G. Methylation of a CTCF-dependent boundary controls imprinted expression of the Igf2 gene. Nature. 2000;405:482-485.
29. Rainier S, Johnson LA, Dobry CJ, et al. Relaxation of imprinted genes in human cancer. Nature. 1993;362:747-749.
30. Ogawa O, Eccles MR, Szeto J, et al. Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumour. Nature. 1993;362:749-751.
31. Steenman MJ, Rainier S, Dobry CJ, et al. Loss of imprinting of IGF2 is linked to reduced expression and abnormal methylation of H19 in Wilms' tumour. Nat Genet. 1994;7:433-439.
32. Moulton T, Crenshaw T, Hao Y, et al. Epigenetic lesions at the H19 locus in Wilms' tumour patients. Nat Genet. 1994;7:440-447.
33. Sparago A, Cerrato F, Vernucci M, et al. Microdeletions in the human H19 DMR result in loss of IGF2 imprinting and Beckwith-Wiedemann syndrome. Nat Genet. 2004;36:958-960.
34. Prawitt D, Enklaar T, Gartner-Rupprecht B, et al. Microdeletion of target sites for insulator protein CTCF in a chromosome 11p15 imprinting center in Beckwith-Wiedemann syndrome and Wilms' tumor. Proc Natl Acad Sci U S A. 2005;102:4085-4090.
35. Cui H, Niemitz EL, Ravenel JD, et al. Loss of imprinting of insulinlike growth factor-II in Wilms' tumor commonly involves altered methylation but not mutations of CTCF or its binding site. Cancer Res. 2001;61:4947-4950.
36. Wang WH, Duan JX, Vu TH, et al. Increased expression of the insulin-like growth factor-II gene in Wilms' tumor is not dependent on loss of genomic imprinting or loss of heterozygosity. J Biol Chem. 1996;271:27863-27870.
37. Okamoto K, Morison IM, Taniguchi T, et al. Epigenetic changes at the insulin-like growth factor II/H19 locus in developing kidney is an early event in Wilms tumorigenesis. Proc Natl Acad Sci U S A. 1997;94:5367-5371.
38. Morison IM, Reeve AE. Insulin-like growth factor 2 and overgrowth: molecular biology and clinical implications. Mol Med Today. 1998;4:110-115.
39. Chao LY, Huff V, Tomlinson G, et al. Genetic mosaicism in normal tissues of Wilms' tumour patients. Nat Genet. 1993;3:127-131.
40. Becroft D, Okamoto K, Morison I, et al. Perilobar nephrogenic rests are associated with epigenetic changes at the IGF2/H19 locus in developing kidney. Pediatr Dev Pathol. 1998;1:251.
41. Ravenel JD, Broman KW, Perlman EJ, et al. Loss of imprinting of insulin-like growth factor-II (IGF2) gene in distinguishing specific biologic subtypes of Wilms tumor. J Natl Cancer Inst. 2001;93:1698-1703.
42. Maw MA, Grundy PE, Millow LJ, et al. A third Wilms' tumor locus on chromosome 16q. Cancer Res. 1992;52:3094-3098.
43. Yeh A, Wei M, Golub SB, et al. Chromosome arm 16q in Wilms tumors: unbalanced chromosomal translocations, loss of heterozygosity, and assessment of the CTCF gene. Genes Chromosomes Cancer. 2002;35:156-163.
44. Mummert SK, Lobanenkov VA, Feinberg AP. Association of chromosome arm 16q loss with loss of imprinting of insulin-like growth factor-II in Wilms tumor. Genes Chromosomes Cancer. 2005;43:155-161.
45. Parkin D, Stiller C, Draper G, et al, eds. International Incidence of Childhood Cancer. Lyon: IARC Scientific Publications; 1988.
46. Stiller CA, Parkin DM. International variations in the incidence of childhood renal tumours. Br J Cancer. 1990;62:1026-1030.
47. Watanabe N, Nakadate H, Haruta M, et al. Association of 11q loss, trisomy 12, and possible 16q loss with loss of imprinting of insulinlike growth factor-II in Wilms tumor. Genes Chromosomes Cancer. 2006;45:592-601.
48. Bliek J, Gicquel C, Maas S, et al. Epigenotyping as a tool for the prediction of tumor risk and tumor type in patients with Beckwith-Wiedemann syndrome (BWS). J Pediatr. 2004;145:796-799.
49. Kobayashi Y, Hata J-I, Sasaki Y, eds. Shouni Geka Byourigaku (Pediatric Surgical Pathology). In: Kobayashi Y, ed. Malformation Syndromes and Pediatric Tumors. 1st ed. Tokyo: Bunkodo; 1995.
50. Cui H, Cruz-Correa M, Giardiello FM, et al. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science. 2003;299:1753-1755.
51. Cui H, Onyango P, Brandenburg S, et al. Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGF2. Cancer Res. 2002;62:6442-6446.